American College of Cardiology (ACC) issued the updated expert consensus decision pathway on the management of mitral regurgitation in April 2020. The whole process in caring patients with mitral valve regurgitation from patient evaluation to treatment choice was discussed in the consensus. The main change from the 2017 version is the confirmation of the effect of transcatheter mitral valve repair on secondary mitral regurgitation. It standardized the process in this field. In this paper, we aimed to introduce the focus update of this consensus.
In recent years, anti-vascular endothelial growth factor (VEGF) therapy has become first line treatment for a variety of clinical conditions, including wet age related macular degeneration, macular edema secondary to retinal vein occlusion, diabetic macular edema and proliferative diabetic retinopathy. With the successive launch of new formulations such as high-dose anti-VEGF drugs and gene therapy in China, sterile intraocular inflammation (SIOI) after intraocular drug delivery has gradually come into public view and warranted attention. On the other hand, a variety of drugs that have been used in ophthalmic clinics for years, including prophylactic anti-infective drugs (such as vancomycin) and glucocorticoids (such as dexamethasone implants), have also been reported of SIOI occurrence. To avoid and alleviate the negative impact of SIOI on the visual function of the affected eyes, a systematic and standardized SIOI management system is urgently needed. For this reason, the Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Committee of Ophthalmologist Branch of Chinese Medical Doctor Association, and Expert Group of Expert consensus for the diagnosis and treatment of sterile intraocular inflammation after intraocular drug delivery (2025) put forward recommended opinions on seven key clinical issues. Based on the latest evidence based medical evidence, combined with international guidelines/consensuses and the current situation of social and economic development in China, they made recommendations on aspects of SIOI, including the incidence and timing, clinical manifestations, related factors and population identification, perioperative monitoring measures, and intervention strategies and prognosis after the occurrence of SIOI, thus forming the Expert consensus for the diagnosis and treatment of sterile intraocular inflammation after intraocular drug delivery (2025). The formulation of this consensus aims to enhance the awareness and understanding of SIOI among ophthalmologists specializing in retinal diseases, provide evidence-based guidance and decision-making references for the early identification and standardized management of SIOI in clinical practice, and further improve the quality control system of intraocular injection therapy in China, thereby ensuring patient safety.
With the recent domestic adoption of novel formulations such as high-dose anti-vascular endothelial growth factor agents and gene therapy drugs, sterile intraocular inflammation (SIOI) following intravitreal injection has gradually come into public awareness and garnered widespread attention. Concurrently, multiple ophthalmic medications with established clinical histories, including prophylactic antibiotics (e.g., vancomycin) and corticosteroids (e.g., triamcinolone acetonide), have also been reported to induce SIOI. To enhance Chinese ophthalmologists’ understanding of SIOI and standardize its diagnostic and therapeutic protocols, the Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association, adhering to evidence-based medicine principles and integrating international guidelines and consensus documents with China’s socio-economic context, have spearheaded the development of the Expert consensus for the diagnosis and treatment of sterile intraocular inflammation after intraocular drug delivery (2025) through rigorous consensus-building processes. This consensus systematically presents diagnosis and treatment recommendations with Chinese characteristics, addressing seven key clinical issues such as the epidemiological features, clinical manifestations, identification of high-risk factors, perioperative management, and prognosis evaluation of SIOI. It focuses on constructing a hierarchical intervention system based on the severity of the disease. An in-depth understanding of the core content of this consensus can, on the one hand, help avoid diagnostic and therapeutic deviations caused by insufficient understanding, and on the other hand, assist in establishing a standardized SIOI management process, thereby effectively reducing the risk of visual impairment and optimizing the visual prognosis of patients. The introduction of this consensus marks the further improvement of the quality management system for intraocular injection therapy in our country and holds significant guiding importance for enhancing the diagnostic and therapeutic level of retinal diseases.
Pathologic myopia-associated macular neovascularization (MMN) is a prevalent clinical ophthalmic condition characterized by pathological changes including lacquer cracks, choroidal neovascularization, and Fuchs spots. Recent advancements in fundus imaging technologies and diagnostic equipment have provided novel perspectives and strategies for the diagnosis, staging, treatment, and follow-up of MMN. The continuous development of various anti-vascular endothelial growth factor agents has effectively preserved visual acuity in pathologic myopia-associated macular neovascularization patients. However, in the clinical practice of MMN, there are still many challenges, such as the lack of unified disease definitions and staging criteria, differences in the criteria for assessing disease activity, the absence of standardized treatment protocols, and the urgent need for optimized follow-up strategies. To address these issues, Fundus Disease Group of Ophthalmological Society of Chinese Medical Association and Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association jointly developed the Expert consensus on standardized diagnosis and treatment of pathologic myopia-associated macular neovascularization in China based on the principles of evidence-based medicine. This consensus systematically outlines the core elements of MMN diagnosis and treatment, including disease definitions and clinical staging criteria, identification of high-risk factors, diagnostic procedures, follow-up management protocols, assessment of disease activity, selection of individualized treatment strategies, criteria for re-treatment, and long-term follow-up strategies. It provides ophthalmologists at all levels with a scientifically standardized and clinically applicable guide. The consensus particularly emphasizes the implementation of precision medicine in clinical practice, and stresses that individualized treatment decisions should be made within the framework of standardized care, taking into account the patient’s visual needs, lesion characteristics, treatment response, and socioeconomic factors.
Pathological myopic tractional maculopathy (MTM), as an important type of macular lesions associated with high myopia, play a significant role in the prevention and treatment of myopic macular diseases. With the rapid development of retinal imaging technologies, especially the widespread application of optical coherence tomography, new technical support has been provided for the accurate diagnosis, clinical staging, treatment decision-making, and long-term follow-up of MTM. However, in clinical practice in China, there are still issues such as unclear definitions, inconsistent staging criteria, and significant differences in treatment strategies. To address these challenges, Fundus Diseases Group in Ophthalmology Branch of Chinese Medical Association and Professional Committee of Fundus Diseases in Ophthalmology Branch of Chinese Medical Doctor Association for Ophthalmologists jointly drafted the Expert consensus on management of pathologic myopic tractional maculopathy in China, based on a systematic literature review and the latest clinical evidence. The consensus was revised multiple times by the core expert group and finally finalized. This consensus systematically establishes a standardized diagnostic and therapeutic system for MTM, covering disease definition and staging, diagnostic pathways and follow-up protocols, treatment strategies based on staging, and surgical intervention plans. It aims to provide ophthalmologists at all levels with a scientifically sound and practically applicable clinical guidance. The development of the consensus strictly adheres to the principles of evidence-based medicine, fully considering the actual clinical conditions of medical institutions at different levels in China. It provides principled recommendations with broad guiding significance for the clinical practice of MTM. It is particularly emphasized that when applying this consensus, clinicians should comprehensively consider the patient’s clinical characteristics, treatment accessibility, and socioeconomic factors, and implement personalized and precise treatment strategies to meet the diverse clinical needs of patients with pathological myopia.